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Abstract
Background While placebo-controlled randomised controlled trials remain the standard way to evaluate drugs for
efficacy, historical data are used extensively across the development cycle. This ranges from supplementing contempo-
rary data to increase the power of trials to cross-trial comparisons in estimating comparative efficacy. In many cases,
these approaches are performed without in-depth review of the context of data, which may lead to bias and incorrect
conclusions.
Methods We discuss the original ‘Pocock’ criteria for the use of historical data and how the use of historical data has
evolved over time. Based on these factors and personal experience, we created a series of questions that may be asked
of historical data, prior to their use. Based on the answers to these questions, various statistical approaches are recom-
mended. The strategy is illustrated with a case study in colorectal cancer.
Results A number of areas need to be considered with historical data, which we split into three categories: outcome
measurement, study/patient characteristics (including setting and inclusion/exclusion criteria), and disease process/inter-
vention effects. Each of these areas may introduce issues if not appropriately handled, while some may preclude the use
of historical data entirely. We present a tool (in the form of a table) for highlighting any such issues. Application of the
tool to a colorectal cancer data set demonstrates under what conditions historical data could be used and what the lim-
itations of such an analysis would be.
Conclusion Historical data can be a powerful tool to augment or compare with contemporary trial data, though cau-
tion is required. We present some of the issues that may be considered when involving historical data and what (if any)
statistical approaches may account for differences between studies. We recommend that, where historical data are to
be used in analyses, potential differences between studies are addressed explicitly.
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Background
Clinical investigations of novel interventions are usu-
ally performed as randomised controlled trials (RCTs)
against placebo or a relevant comparator. Although
RCTs in which all patients are randomised to either the
intervention or control treatment are the standard
approach for comparing efficacy, there is interest in
making use of historical data to reduce the need for
contemporary controls. The historical data can, in prin-
ciple, increase the power of tests for treatment efficacy
and improve precision of the estimates. In some cases
(e.g. in rare/orphan diseases), the use of historical data
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is necessary to obtain a sufficiently powered analysis,
due to the limited number of patients available for ran-
domisation. In principle, both intervention and control
patients of previous studies can be combined with data
of the current study. Previous studies typically do not
feature exactly the same intervention and control treat-
ment, and especially the intervention may change
between trials. Therefore, the focus lies on combining
historical control patients with patients randomised to
the control in the current study. The combination of
historical and randomised controls to supplement the
analysis of contemporary or future clinical trials was
popularised by Pocock.1 The main concern with the
use of historical data is the possibility that the histori-
cal studies differ in characteristics with the current
study, due to, for example, improvement in supportive
care over time, differences in patient selection, and
between-centre differences. Indeed, previous work has
demonstrated substantial bias when comparing the out-
comes of comparisons made using observational data
to RCTs conducted in the same population.2–7 This
finding was also quantified in a simulation study.8
To overcome the issues discussed above, Pocock
suggested criteria that should be met for the historical
data to be deemed ‘acceptable’. These criteria are pre-
sented in Figure 1. Provided the criteria are met, the
suggestion is that the historical data may be combined
with contemporary randomised controls, thereby
reducing the number of patients required in the control
arm. Since the use of historical controls was originally
proposed, their application has proliferated beyond the
pooling of placebo data from sequential studies to
include areas, such as sample size calculations, synth-
esis of published historical data, and comparative effi-
cacy analyses for treatments, which are granted a
marketing authorisation on the basis of uncontrolled
studies.9,10 Additional relevant criteria for the accept-
ability of historical data are drift, exchangeability, and
conditional exchangeability.11 Drift can be defined as a
bias (difference in underlying model parameters)
between the historical data and current data, which can
arise due to general improvements in supportive care
over time. Exchangeability implies that the historical
studies and the current study constitute a random sam-
ple from a population of studies, whereas conditional
exchangeability implies that the studies constitute a
random sample from a population of studies only after
accounting for differences in patient characteristics.
Conditional exchangeability applies more generally
than exchangeability. Under these criteria, meta-
analytic approaches for combining the historical and
current controls may be applied. The use of historical
data has proven to be a useful tool for studies on
orphan diseases,12,13 whereas it remains controversial
in the primary analysis of a phase III RCT.
Historical controls may originate from a previous
study of the same group/institution, from the literature,
or from other sources (for example, patient registries).
However, such data only occasionally meet the criteria
set out originally by Pocock in an exact manner, which
specify that the historical studies must have been con-
ducted by the same investigators, have similar patient
characteristics, and must have been done in roughly the
same time period. Since such cross-study comparisons
are of considerable interest, one could make use of
techniques, such as propensity score matching,14 among
others,15 which allow some of these barriers to be
addressed. Depending on the reason for the use of his-
torical controls and the purpose of the analysis, some
of the Pocock criteria could be relaxed with the use of
appropriate methodology without introducing bias.
Likewise where multiple studies are available, there
may be a desire to use all studies, but with different
weightings.
Given the developments in statistical methodology,
trial design, and medical research practice since the
1976 paper of Pocock, the objective of this article is to
describe an updated tool for assessing the similarity
between historical and contemporary data. With this
aim in mind, we develop a set of questions which may
help identify areas that differ between studies (whether
in design, patients, or setting). We also discuss poten-
tially appropriate statistical methods by which histori-
cal data may still be utilised in case data sets are not
perfectly aligned. The application of the resulting tool is
illustrated with an example of cetuximab compared to
standard care in colorectal cancer. Our hope is that by
highlighting the relevant issues (and signposting meth-
odologies) the tool enables analysts to better under-
stand the issues with historical data and justify the
choice of methodology used for analysis.
Methods
We aim to identify the relevant different aspects
between historical and current studies that should be
taken into account when historical data are considered
to be included in the analysis. Pocock’s original criteria
serve as the starting point for the development of the
tool. In addition, we considered the statistical assump-
tions implicit in the use of historical data, and which
differences between studies could result in violations of
those assumptions. These statistical considerations are
described in Supplemental Appendix 1, together with
the resulting insights used to augment the proposed
tool.
In order to ascertain whether historical data set(s)
may be sufficiently similar for use alongside current
data (for instance, with some form of combining), the
process by which outcomes were obtained should be
understood. This means there is a need to compare the
treatments given and the circumstances of the studies–
for example, patient characteristics. We therefore divide
608 Clinical Trials 17(6)
the relevant issues into three areas (outcome measure-
ment, study and patient characteristics, and disease pro-
cess and intervention effects) and discuss each in turn.
These issues are illustrated statistically in Supplemental
Appendix 1 and described in non-technical language
below. These areas are subsequently used to derive
questions that can help identify the relevant differences
between studies.
Outcome measurement
One of the changes that can occur over time is the way
outcomes are measured. For example, as technology
has advanced, tests have become more sensitive, and
definitions have evolved – for example, the widely used
Common Terminology Criteria for Adverse Events
(CTCAE) are now at version 4.0. There have also been
changes in the types of outcomes used in studies over
time, for instance, moving from response rates to med-
ian survival, and then subsequently beyond to end-
points such as restricted mean survival time.16 Any
differences in how outcomes are measured/defined (or
in the type of outcome) should therefore be understood
and accounted for – for example, by reanalysis of the
contemporary trial or mapping between endpoints –
even if outcomes are named similarly, for example, par-
tial response, the definition may have changed over
time. If the differences between studies cannot be
bridged, the historical data may need to be discarded.
Study and patient characteristics
In order to combine the historical data with current
data, the inputs to the process by which outcomes are
generated, that is, the interaction of the disease process
and the mechanism of action of any interventions, must
remain similar. In practice, this implies that the study
inclusion criteria and the individual patient characteris-
tics should be assessed for similarity between the histor-
ical studies and the current study. If these are not fully
aligned, for example, if the historical patients and the
current patients exhibit different characteristics, statisti-
cal methods accounting for this imbalance across stud-
ies may be required (which are likely to, correctly,
increase the uncertainty around estimates).
If there is little overlap in patient characteristics or if
there are structural differences in inclusion criteria, the
historical studies and current study may be incompati-
ble, such that no statistical adjustment method would
be able to overcome the unquantifiable bias. An exam-
ple here would be if some but not all studies required
patients to first complete a ‘wash-out’ period from their
previous treatment. This implies that only patients who
survive to the beginning of the study (a form of immor-
tal time bias)17 are included in the results.
Disease process and intervention effects
Furthermore, the way in which outcomes are achieved
must be similar across studies. However, differences
1. The historical group(s) must have received a precisely defined standard 
treatment which must be the same as the treatment for the randomised 
control.
2. The historical group(s) must have been part of a recent clinical study which 
contains the same requirements for paent eligibility.
3. The methods of treatment evaluaon must be the same for the historical 
group(s) and the current control group.
4. The distribuon of important paent characteriscs in the historical 
group(s) should be comparable with those in the new trial.
5. The historical study/studies must have been performed in the same 
organizaon with largely the same clinical invesgators.
6. There must be no other indicaons leading one to expect differing results 
between the randomized and historical control group(s). For instance, more 
rapid accrual on the new study might lead one to suspect less enthusiasc 
parcipaon of invesgators in the previous study so that the process of 
paent selecon may have been different
Figure 1. Acceptability conditions proposed by Pocock regarding the use of a historical control group.
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may arise for several reasons. For example, changes in
supportive care over time may improve outcomes, even
if the intervention remains unchanged. Alternatively,
interventions may change over time as their usage is
refined, or protocols in different centres may prescribe
a different usage. For example, the use of stem cell
transplantation has been continually refined over time,
with improvements in both short-term and long-term
mortality.18
It is also possible that the impact of the disease
changes over time – either as screening improves result-
ing in earlier diagnosis (and patients with a more
favourable outcome) or as a new treatment is intro-
duced at early stage disease, meaning patients who do
progress have much more severe disease subtypes. It is
also possible that the disease itself changes in the case
of pathogens, which may evolve over time or become
resistant to treatments (as seen with influenza, bacterial
infection, and HIV).
Application to illustrative example: cetuximab in
metastatic colorectal cancer
To illustrate and evaluate the proposed framework, it
was applied to a motivating example of a historical
controlled study conducted by Annemans et al.19 of
cetuximab in metastatic colorectal cancer (mCRC)
(Figure 2). Cetuximab was licenced on the basis of the
BOND study (see Cunningham et al.20), an RCT of
329 patients which compared cetuximab plus irinotecan
versus cetuximab monotherapy in 11 centres across
Europe. This study design addressed the benefit of
Queson Jusficaon Illustraon of the issue
1. Study tle and year - -
2. In what calendar period 
were paents enrolled?
Structural changes in populaons and healthcare systems 
over me make older studies less relevant – for example 
increasing life expectancy, and earlier diagnosis of 
disease/different criteria used for diagnosis changing the 
paent group at each line of treatment. 
Studies in melanoma in the 1970s1, despite using the same 
comparator as in 2011 37, are unlikely to be generalisable due to 
major changes in both the populaon under study and wider 
changes in healthcare.
3. What is the design of 
the study?
Mulple studies have found differences in outcomes for 
the same intervenon depending on study seng e.g. 
trial versus registry (regardless of paent characteriscs).
Randomised arms of trials performed 5% beer than historical 
controls in me-to-event endpoints for the same outcome5. Trials 
(compared to registries or case series) may also have had 
selecon on unobservable characteriscs of paents, where only 
paents with the capacity to benefit were entered.
4. What are the locaon 
and seng of the study?
The geographical locaon paents were recruited from 
may be relevant for comparability, similarly studies 
conducted in different healthcare sengs may implicitly 
select paents – for example teaching hospitals may 
have the fiest (or alternavely worst prognosis) 
paents in an area referred to them for specialist 
treatment.
In the trial of cabazitaxel for prostate cancer, differences were 
seen in the effecveness of treatment by geographic region, 
potenally related to the level of pre-treatment received38.
5. What were the inclusion 
and exclusion criteria?
How paents were recruited could lead to a selected 
sample with bias in any resulng comparison or 
synthesis.
Cancer clinical trials will oen exclude paents with poor 
performance status or disease subtypes with a poor prognosis 
(such as brain metastases), who would be included in registry 
studies 37,39.
6. What was the 
intervenon used?
The comparability (and suitability to perform a 
comparison or synthesis) depends not only on the 
intervenon, but also on the supporve care received by 
paents
In studies in chronic idiopathic thrombocytopenia, the control arm 
for both eltrombopag and romiplosm clinical trials was ‘placebo’, 
however with differences in allowable concomitant medicaons 
and salvage therapies40,41 .
7. What endpoints were 
reported and how were 
they measured?
Endpoints should be comparable, otherwise there may 
be a bias or render a comparison invalid. This includes 
both differences in endpoints (for example me to 
progression versus progression-free survival), or 
differences in how endpoints are measured or defined 
Differences in oncology trials are commonly seen between 
invesgator and independent measures of progression42, equally 
studies may report different mepoints, or use different scales for 
response. If possible, endpoints may need to be reanalysed using 
different criteria or mapped.
over me (which includes the sensivity of instruments 
to detect low level disease)
8. How many paents 
were enrolled in the 
studies?
The relave size of studies will determine appropriate 
methodologies for any stascal adjustments required, 
whilst also providing context for any differences between 
studies (and how likely these are to be a result of 
chance).
If the number of historical controls considerably exceeds the 
number of contemporary controls, greater downweighng of the 
historical controls should be considered. Alternavely if the 
number of acceptable historical controls is relavely small, 
analysis of only the contemporary data may suffice.
9. Present a tabulaon of 
study outcomes
To enable comparisons between studies, and allow 
differences in relaonships between outcomes to be 
assessed.
Studies may report similar median PFS, however the profile of 
survival curves may be extremely different – for example between 
immunotherapies and targeted therapies43. Presentaon of all 
results will allow inspecon of similarity and help understand how 
these may be modelled. 




Relevant disease-specific and paent characteriscs 
(even if not predicve of outcome) should be compared 
side by side to understand differences in paent 
populaons
Differences in prognosc variables may need to be adjusted for in 
models, whilst this may not be possible in the case of large 
disparies. Differences in non-prognosc variables may hint 
towards differences in unobservable characteriscs.
Figure 2. Motivating example: Cetuximab in metastatic colorectal cancer.
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combination therapy, which was shown to provide a
higher response rate than monotherapy (22.9% versus
10.8%), but did not provide an estimate of the efficacy
of cetuximab versus standard care. To make such a
comparison for the benefit of reimbursement agencies,
Annemans et al.19 conducted a retrospective review of
patient notes to identify untreated patients from the
largest centres in BOND. This investigation was con-
ducted in the three largest centres, enrolling 66 patients
who received standard care in the same centres, but
outside the period the cetuximab trial was ongoing.
The tool was therefore used to evaluate the comparison
of these two studies.
Results
Using Pocock’s criteria as a starting point, we updated
and more elaborately described the issues that are rele-
vant for incorporating historical data, which yielded
the proposed tool for assessing historical data that is
presented in Figure 3. In this figure, each issue is high-
lighted with a reference to the literature illustrating the
issue.
The areas of importance are the patient characteris-
tics, precise intervention used (including supportive
care), outcome measurement, and patient selection to
the study. The statistical/methodological rationale for
the question as well as an example of how studies may
be non-comparable and the impact on any compari-
son(s) are given alongside each question. The tool in
Figure 3 may be used to identify areas where historical
controls differ from contemporary data, and as a result
whether statistical adjustments may be required, or
where there are such important differences that only
narrative comparisons are warranted.
The items in the tool do have a large degree of over-
lap with the criteria proposed by Pocock; however, they
are different in nature. Rather than proposing a set of
dichotomous criteria that must all be met to allow for
pooling or synthesis of the studies, our proposed tool
instead seeks to present relevant data and study design
aspects and to identify and quantify differences, giving
a more nuanced picture. This is in line with the aim of
comparing between studies and allowing a judgement
to be made of the appropriate next steps. The main
additions we make to the original criteria pertain to the
study design and the patient selection, which in the
original Pocock criteria were taken to be placebo arms
from the same centre. The tool also asks for the study
results to be presented for comparison, as these may
indicate differences between studies (if the same inter-
vention is used in both arms) or be required for the use
of statistical methods such as ‘test then pool’ as a next
step.21
Illustrative example: cetuximab in mCRC
The study by Annemans et al. appears to be of high
quality in attempting to identify similar patients to
those from the clinical trials, from the same centres and
date range – although imperfect, it is a pragmatic
attempt to estimate the outcomes of standard care
without availability of RCT or network of trials.
Using our proposed tool, it is apparent that,
although the largest centres from the Cunningham
et al.’s study were used as the source of control data,
there may be differences between these studies and the
other centres enrolled – due to their size or their loca-
tion (Belgium, France, and Italy) being unrepresenta-
tive. To present a valid comparison between
combination therapy and standard care, a useful next
step would be to inspect the subsample of the
Cunningham et al.’s study using only the centres
enrolled in the Annemans et al.’s study. The patient
characteristics for the Annemans et al.’s study are not
given in the publication even at the aggregate level – to
be confident in the use of these data as a historical con-
trol, the distribution of patient characteristics should
be shown.
Provided there is good overlap between the study
characteristics and patient characteristics within the
studies, the use of the Annemans et al.’s data as a his-
torical control would seem appropriate, provided it is
used with suitable statistical techniques (which may
involve either matching or weighting methods). To per-
form any statistical adjustments in this example, access
would be required to the patient-level data from both
studies. The main limitation of such a comparison is
also highlighted through the use of our proposed table,
which clearly identifies that only overall survival (OS)
1. Current controls only: Discard the historical data, and analyse only the data 
of the current study 
2. Test-then-pool: Perform a stascal test to assess the differences between 
the historical and current controls, and should the studies be similar, allow 
pooling21,44,45 
3. Power prior methods: Use the historical data to form a prior distribuon for 
a Bayesian analysis of the current study, but with downweighng of the 
historical data24,46,47 
4. Hierarchical methods: meta-analyc methods with study-specific 
parameters for all studies, but with the assumpon that the model 
parameters of different studies originate from a common distribuon, 
thereby enabling the historical data to inform the predicons of the model 
parameters for the current study48,49 
5. Pooled analysis: combine the historical and the current controls in a single 
analysis, without stascal adjustment. This method is implicitly used in the 
case of uncontrolled studies (where the number of current controls is 0) 
Figure 3. Questions and justifications regarding important
items for historical controls.
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is available in the Annemans et al.’s data set.
Comparisons on the primary endpoint of the
Cunningham et al.’s study (response rate) or time to
progression are not possible without the use of further
assumptions.
Appropriate statistical methods
A variety of methods has been proposed to account for
differences in observed patient characteristics between
historical and contemporary data. These methods
include the aforementioned use of not only propensity
scores but also meta-regression,22 matching-adjusted
indirect comparisons,23 simulated treatment compari-
sons,24 and other regression-based techniques25– each
of which have varying data requirements.
If there is a desire to perform a combined analysis of
historical and contemporary data, an appropriate sta-
tistical method or methodology to adjust for study-
specific effects and other potentially unobservable dif-
ferences between studies is required; see Wadsworth
et al.26 for a systematic review. A selection of tech-
niques that perform adjustments for between-study dif-
ferences is presented in Figure 4, with the ordering of
techniques based on how stringent the required assump-
tions regarding comparability are. These techniques
range from simply discarding the historical data to
‘naı̈ve’ pooling of historical and contemporary evi-
dence. The former of these methods is appropriate if
there are irreconcilable differences between historical
and current controls, while the latter is acceptable only
if the historical and current controls originate from
essentially the same study – a criterion that seldom
applies.
The remaining three highlighted methods (test then
pool, power priors, and hierarchical methods) can be
used in intermediate situations, where there are no
insurmountable differences in outcome measures,
patient characteristics, and disease process/intervention
effect, but some adjustment is still necessary. Most
implementations of these methods perform ‘dynamic
borrowing’, that is, the information in the historical
controls is given a lower weight in the analysis depend-
ing on the size of the observed differences between his-
torical and contemporary controls – the more similar
the data, the higher weight assigned to the historical
data. Recent simulation studies have shown that the
three intermediate methods (test-then-pool, power
prior, and meta-analytic methods) may suitably
account for between-study differences and may also be
used to control the type I error rate. In particular, the
meta-analytic methods appear to lead to the largest
reduction in bias and ability to control the type I error
rate.27 New variants and adaptations of these methods
are frequently proposed such as a test-then-pool
approach based on equivalence tests,28 extensions of
the power prior to data with multiple historical studies,
and combinations of these methods.29 However, none
of these methods are guaranteed to control the type I
error rate at the nominal 5% level.30 While these tech-
niques are aimed at accounting for between-study het-
erogeneity (which is unobserved), in the case of
observed differences, for example, patient characteris-
tics, these methods may need to be augmented either
with adjustment techniques or by including the relevant
patient characteristics as covariates in the statistical
model.
The ‘naı̈ve’ pooling of studies is the final method in
the list, which implies that no kind of statistical adjust-
ment is made for differences between historical and cur-
rent controls. We believe that there are applications
where pooling data may be appropriate, however, only
if the strictest criteria for comparability are met, and
between-study differences can virtually be ruled out.
Potential examples of such applications are the example
given in the 1976 paper (sequential studies in a single
centre, if appropriate) and some studies used for US
Food and Drug Administration approvals. At times,
two RCTs are conducted in parallel with essentially the
same protocol and time frame, but in different centres –
should these circumstances be met, patients may be
allocated by the instrument of geography into one study
or the other. Even in such cases (effective allocation by
time or geography) between-study differences should be
investigated and naı̈ve pooling should be used with
extreme caution.
Discussion
The questions identified in our tool lead to a summary
of relevant information of the historical controls. From
this information, we can identify where data are suit-
able for pooling (i.e. rarely), where they could be used
with statistical adjustment, or alternatively where the
review may highlight that an informative comparison
between studies is not possible. The questions included
in the table represent key areas where studies may dif-
fer, collated based on Pocock’s original criteria, statisti-
cal theory, and the experience of the authors. The
novelty of this tool is that it provides a framework for
systematically comparing a historical study to a current
study, using both the observed data and the study
designs, while leaving necessary room for debate.
Except for the work of Pocock, few authors have dis-
cussed or proposed clear criteria for choosing historical
data. See the work of Lim et al.31,32 for a broader
review of general principles to consider when selecting
and incorporating historical control data.
Because a single major difference can render a com-
parison between studies inappropriate (in line with the
general experience from quality scores for clinical stud-
ies), we do not suggest to use the tool to score trials in
an objective and quantitative manner. However, we
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hope that in answering the questions presented, a
strong basis for a decision on the comparability of stud-
ies may be achieved. When compared with Pocock’s
original criteria, the questions ask for details of the
studies, instead of asking if they are the same. This is in
keeping with the different objective, of understanding
the similarity of studies for further analysis – we then
highlight a variety of techniques that may aid the
analyst in conducting such pooling. While there is an
unavoidable need for judgement of similarity, and when
different methods would be appropriate, we would
hope that this at least makes such decisions explicit,
rather than implicit.
The proposed criteria do not yield an unequivocal
decision of whether the historical data are to be consid-
ered ‘acceptable’. However, the criteria should enable
Study tle and year Cunningham et al. 2004
(contemporary trial)
Annemans et al. 2007 
(historical control)
What dates were 
paents enrolled?
July 2001 to May 2002 Outside of the Cunningham et al. 
enrolment dates (July 2001 to 
November 2002), exact dates not 
given
What is the design 
of the study?
Phase III randomised trial Case series, with all paents 
considered, and those matching the 
inclusion criteria for the Cunningham 
et al. study included.
What are the 
locaon and 
seng of the 
study?
56 Trial centres in 11 European 
countries
The largest centres for the 
Cunningham et al. study, located in 
France, Belgium and Italy





Metastac colorectal cancer with 
pre-study irinotecan with 
documented disease progression, full 
inclusion criteria not stated
Metastac colorectal cancer treated 
with prior irinotecan with 
documented disease progression, full 
inclusion criteria not stated
What was the 
intervenon used?
Weekly cetuximab at 400 mg per 
square metre for the first infusion 
and 250 mg per square metre for 
subsequent infusions with irinotecan 
at the dose paents had received 
previously
Current care, defined as whatever 
treatment the paent received in 
pracce
What endpoints 
were reported and 
how were they 
measured?
Primary outcome of response rate 
evaluated by the treang physician 
and independent review commiee 
using the WHO criteria. Time to 
progression and overall survival 
reported as secondary outcomes
Overall survival, no time to 
progression or response rates were 
reported
How many paents 
were enrolled in 
the study?
218 for the cetuximab + irinotecan 
combinaon arm (219 in total)
66
Present a 











Median TTP 4.1 months

































NR, Not Reported; NA Not Available
Figure 4. Recognised statistical methods for the use of historical data.
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researchers to make an assessment of whether there is a
risk of drift (systematic bias in the historical data com-
pared to the current data) and whether the assumption
of exchangeability or conditional exchangeability is
reasonable. Exchangeability is an assumption that is
relatively difficult to demonstrate and communicate,
whereas drift (bias) seems more straightforward.
Nevertheless, we believe that both drift and exchange-
ability are useful criteria for assessing historical data
and choosing an appropriate analysis method. Previous
simulation work showed that some dynamic borrowing
methods are relatively robust as long as the historical
data are (conditionally) exchangeable, whereas even a
small systematic bias in the historical data threatened
the performance of these methods and led to inflated
type I error rates.27 Drift due to improvements in care
over time is also an important concern in practice. In a
meta-analysis by Snyders et al.,33 who looked at 63
trials of docetaxel in lung cancer (enrolling over 10,000
patients), it was found that outcomes improved each
year by a mean of 0.3% in objective response rate
(ORR), 0.5% for progression-free survival (PFS), and
0.9% in OS. These changes over time imply that histor-
ical data that are more than say 10 years old for doce-
taxel in this indication should be avoided. The rate of
drift in other diseases will differ, but the potential for
change is something the analyst should be aware of.
The application of the tool is illustrated by our moti-
vating example, where it highlights the differences
between studies and leads naturally to the next steps
required for comparisons to be drawn. In the majority
of cases, these next steps will consist of further statisti-
cal analysis which may be as simple as trimming data
sets to ensure entry criteria are similar or may involve
more complex modelling as mapping between out-
comes and weighting of patients. Where multiple stud-
ies are available, more complex techniques may be
needed such as those highlighted in Figure 4. The tool
may also highlight that the differences between studies
are too great, so that some or all historical studies
should be omitted from the analysis.
The main advantage of the proposed tool is that in a
side-by-side comparison, differences between studies
are highlighted, and their importance can be discussed
as opposed to simply referred to as a ‘historical con-
trol’. The tool can then be presented as a single table or
figure in a journal article or evidence dossier for sub-
mission to regulatory bodies or payers. Its use would
also not represent additional burden, as should histori-
cal data be used, it is reasonable to expect the detail of
the comparison to be provided (if anything, this burden
should reduce).
The main limitation of the proposed tool is that it is
not possible to know whether there exists a bias even in
trials that appear superficially similar. This is particu-
larly the case in the case of uncontrolled studies – in
such instances, it is not possible to compare control
arms to assess between-study variation, which has been
highlighted in the literature as an area of concern34 and
for future research.25 Despite this limitation, uncon-
trolled studies with carefully selected historical controls
should be preferable to uncontrolled studies that com-
pare observed outcomes to an assumed outcome so
that sampling variability in the historical data is
ignored, or, even worse, when the response rate under
the null hypothesis lacks a clear data-based justifica-
tion.35 Similarly, there may be other biases present; for
instance, a sponsor may only commission a Phase 3
study following promising results in Phase 2 – a finding
which has been seen with medical interventions, in gen-
eral.36 Beyond these limitations, we would also note
that the particular tools that should be used for statisti-
cal adjustments are not specified and do rely on judge-
ment as there is no easily quantifiable decision rule or
flowchart to choose the type of statistical technique.
While the use of historical controls does not repre-
sent the highest level of data on the ‘evidence pyramid’,
in many circumstances, such as rare cancers, orphan
diseases, and some Class 3 medical devices, their use is
necessary. In other cases, appropriate use of historical
data may be seen to be more ethical by reducing the
need to expose patients to control treatments and
reducing the cost of trials. The tool we present may
help improve the quality and appropriateness of such
historical comparisons in a variety of settings. With
appropriate use of historical data (collected at great
financial and human cost), the quality of decision-
making by clinicians, regulators, and payers could
improve, ultimately leading to better patient outcomes.
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